Intelligence · Clinical Pipeline
Neurology & CNS R&D Pipeline
Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.
- Programs
- 676
Quick answer
Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.
Top sponsors
- HOFFMANN-LA ROCHE 38 programs
- Teva Pharma 37 programs
- Takeda 32 programs
- BRIGHT MINDS BIOSCIENCES 30 programs
- United Therapeutics Europe 26 programs
- Chinese Academy of 24 programs
- Anaxis Pharma 22 programs
- Novartis India 21 programs
- Jazz Pharmaceuticals Ireland 20 programs
- NEUROCRINE BIOSCIENCES 18 programs
- SUPERNUS PHARMACEUTICALS 18 programs
- Acadia Pharmaceuticals 16 programs
-
[18F]APN-1607
The First People's Hospital of Lianyungang
Alzheimer Disease
1 trial -
anti-thymocyte globulin
Ultragenyx UK Limited
Multiple Sclerosis
1 trial -
cyclophosphamide
Ultragenyx UK Limited
Multiple Sclerosis
1 trial -
high-fat diet group（AD16 20mg）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Alzheimer Disease
1 trial -
ketamine
Summit Therapeutics
Multiple Sclerosis
1 trial -
monoclonal antibody M-T412
Ultragenyx UK Limited
Multiple Sclerosis
1 trial -
sabirnetug (ACU193)
Acumen Pharmaceuticals
Alzheimer Disease
1 trial -
A Phase 1, Open-Label, Multiple-Part Trial to Evaluate the Drug-Drug Interaction Potential of PRAX-628 in Healthy Participants
Chongqing Precision Biotech Co., Ltd
Epilepsy
1 trial -
AGEE cream
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
APOKYN
SUPERNUS PHARMACEUTICALS, INC.
Parkinson's Disease
2 trials -
Alcohol Wipes vs. No Alcohol Wipes
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
Antiepileptic drug therapy
United Therapeutics Europe Ltd
Epilepsy
1 trial -
Aripiprazole
Otsuka Beijing Research Institute
Schizophrenia
3 trials -
Brand lamotrigine
BRIGHT MINDS BIOSCIENCES INC.
Epilepsy
1 trial -
Butylphthalide
The First People's Hospital of Lianyungang
Focal Epilepsy
1 trial -
CREXONT ER
Amneal Pharma Europe Ltd
Parkinson Disease
2 trials -
Cannabidiol Oral Solution [Epidiolex]
Jazz Pharmaceuticals Ireland Limited
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
1 trial -
Clozapine
BRIGHT MINDS BIOSCIENCES INC.
Schizophrenia
1 trial -
Copaxone
Teva Pharma GmbH
Multiple Sclerosis
2 trials -
DONEPEZIL, DONEPEZIL
Pari Pharma GmbH
Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease
1 trial -
Desvenlafaxine Succinate
Grace Therapeutics
Vascular Depression
1 trial -
Dexmedetomidine
BioXcel Therapeutics
Schizophrenia Agitation
1 trial -
Dexmedetomidine Injectable Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Epilepsy
1 trial -
Dimethyl fumarate
Biogen
Multiple Sclerosis
1 trial -
Esketamine
The First People's Hospital of Lianyungang
Postpartum Depression
1 trial -
Folic Acid
Cardiff Oncology
Depression
1 trial -
Glatiramer Acetate
Teva Pharma GmbH
Relapsing Remitting Multiple Sclerosis
5 trials -
Iloperidone
Vanda Pharmaceuticals Netherlands B.V.
Schizophrenia
5 trials -
Kesimpta 20 mg solution for injection in pre-filled syringe
Novartis Pharmaceuticals
Relapsing forms of Multiple Sclerosis (RMS)
1 trial -
Ketamine
Teva Pharma GmbH
Treatment Resistant Depression
1 trial -
Lecanemab 10 mg/kg
The First People's Hospital of Lianyungang
Alzheimer s Disease
1 trial -
Lubiprostone
Takeda
Multiple Sclerosis
1 trial -
MIYAIRI 588
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Depression Mild
1 trial -
Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets, Mayzent 1 mg film-coated tablets, BAF312, BAF312, BAF312
Verona Pharma Ireland Limited
Active progressive multiple sclerosis course after an initial relapse clinical course
1 trial -
Minocycline
BRIGHT MINDS BIOSCIENCES INC.
Schizophrenia
1 trial -
Ocrevus 300 mg concentrate for solution for infusion
Hoffmann-La Roche
Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]
1 trial -
Ofatumumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
1 trial -
Oral Zonisamide Therapy
Affiliated Hospital of Nantong University
Epilepsies, Partial
1 trial -
PERSERIS
Indivior Pty Ltd
Schizophrenia
1 trial -
Paliperidone ER
Hospital Authority, Hong Kong
Schizophrenia
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Parkinson Disease Psychosis
1 trial -
RITALINE L.P. 10 mg, gélule à libération prolongée
Tour Hekla
Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).
1 trial -
RIVASTIGMINE, Rivastigmin adhesive plaster 9.5 mg placebo containing 0 mg of rivastigmin, Rivastigmin adhesive plaster 4.6 mg placebo containing 0 mg of rivastigmin, RIVASTIGMINE
Disc Medicine
Depression
1 trial -
ROP
GlaxoSmithKline
Parkinson Disease
1 trial -
Ramelteon
Takeda
Schizophrenia
1 trial -
Rasagiline
Teva Pharma GmbH
Parkinson's Disease
5 trials -
Rasagiline Mesylate
Teva Pharma GmbH
Parkinson's Disease
8 trials -
Rasagiline/Placebo
Teva Pharma GmbH
Parkinson's Disease
1 trial
Frequently asked questions
How many neurology & cns pipeline programs are tracked?
676 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.
Data attribution: Data sources · All pipeline programs